Stay updated with breaking news from Advicenne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory News: Advicenne (Euronext: ADVIC) (Paris:ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal
Advicenne will receive a transfer price and royalties for an amount markedly higher than 50% of future sales of Sibnayal - Sibnayal will be marketed to one-third of European patients by three members
Regulatory News: Advicenne (Euronext: ADVIC) (Paris:ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal
20.12.2021 - Regulatory News: Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces is has received a positive opinion from the ... Seite 1
Regulatory News: At its meeting today, the Board of Directors of Advicenne (FR0013296746 ADVIC the "Company") (Paris:ADVIC) (BSE:ADVIC) decided to submit to the ordinary general meeting of shareholders